

Call for Entries

Astellas Research Competition Supports Canadian Investigators



Markham, Ontario – August 6, 2009 – Astellas Pharma Canada has announced the second annual Astellas Research Competition (ARC), part of its broad corporate effort to advance scientific knowledge in dermatology and urology with a view to improving patient care and ultimately quality of life.

Health care professionals who are interested in participating in this research competition are invited to review the application process (including eligibility and selection criteria) at the Astellas Pharma Canada website at www.astellas.com/ca.

Eligible research proposals in dermatology may include conditions such as atopic dermatitis, psoriasis (all types), and vitiligo. For urology research projects, eligible proposals include: overactive bladder, lower urinary tract syndrome, and pelvic floor disorders.

All eligible proposals will be reviewed on the basis of scientific validity, integrity, clinical relevance, and feasibility. Five research grants will be awarded for the 2009/10 competition, each for a maximum amount of \$75,000 CDN. Funding is based on a per-study amount and is non-renewable. The deadline for applications is **September 25, 2009** and the recipients will be announced on **November 27th, 2009**.

"Astellas Pharma Canada is proud to support the ingenuity of Canadian investigators as a research and development partner within the Canadian scientific community," said Fumiaki Sakurai, Astellas Pharma Canada President. "Through the Astellas Research Competition we are confident that the results of this research will manifest itself in new and better clinical supports for individuals with skin disease and urological disorders, making a significant difference in their lives."

The 2008/2009 Grant Recipients

In the first year of the competition, some of our grant recipients in urology and dermatology included **Dr. Stéphane Bolduc**, Laboratoire d'Organogénèse Expérimentale (LOEX), Laval University for his project on the *Construction of a Tissue Engineered Autologous Genitourinary Tissue Graft*, **Dr. Jacques Corcos**, Jewish General Hospital for his work on *Bone marrow mesenchymal stromal cell therapy for restoration of sphincteric and bladder wall defect*, and **Dr. Wayne Gulliver**, NewLab Clinical Research Inc. for *Genetics, Pharmacogenetics, and Pharmacogenomics of Psoriasis and Related Psoriasis Comorbidities in relationship to Amevive Treatment*.

For a complete list of the 2008/09 grant recipients, please visit the Astellas Pharma Canada website ARC link.

About Astellas Pharma Canada, Inc.

Astellas Pharma Canada, Inc. is highly focused on customers and their needs and is committed to making a difference in immunology. The company also seeks to develop breakthrough products in infectious disease, urology, cardiovascular disease and dermatology. Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas Pharma Canada, Inc., is one of the Astellas Group of companies in North America and an affiliate of Astellas Pharma Inc., located in Tokyo. The organization is committed to becoming a global pharmaceutical leader by combining outstanding R&D and marketing capabilities. Additional corporate information is available at www.astellas.com/ca.